Lataa...
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody...
Tallennettuna:
| Julkaisussa: | Iran Biomed J |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Pasteur Institute
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889503/ https://ncbi.nlm.nih.gov/pubmed/28992681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22034/ibj.22.3.180 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|